Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 2, Parallel, Comparator-Controlled Trial to Evaluate the Safety and Efficacy of LY3209590 in Insulin-Naïve Patients With Type 2 Diabetes Mellitus

Next Previous
Trial Profile

A Phase 2, Parallel, Comparator-Controlled Trial to Evaluate the Safety and Efficacy of LY3209590 in Insulin-Naïve Patients With Type 2 Diabetes Mellitus

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 02 Nov 2023

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Insulin degludec (Primary) ; Insulin efsitora alfa (Primary)
  • Indications Type 2 diabetes mellitus
  • Focus Therapeutic Use
  • Sponsors Eli Lilly and Company

Most Recent Events

  • 06 Oct 2023 Results of pooled analysis (n=942 from studies NCT04450394, NCT04450407, NCT03736785) comparing glycaemic control and hypoglycaemia risk during the first 6 weeks of treatment with efsitora or degludecpresented at the 59th Annual Meeting of the European Association for the Study of Diabetes
  • 06 Oct 2023 Results of pooled analysis (n=912 from studies NCT04450394, NCT04450407, NCT03736785) assessing similarities and differences in glu-cose during treatment with daily or weekly basal insulin administration presented at the 59th Annual Meeting of the European Association for the Study of Diabetes
  • 12 Mar 2023 Results assessing assessed the safety and efficacy of BIF versus degludec in insulin-naive patients with type 2 diabetes published in the Diabetes Care

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top